These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 15190298)

  • 1. PET scan in the therapeutic strategy.
    Haioun C; Itti E; Rahmouni A; Meignan M; Reyes F
    Hematol J; 2004; 5 Suppl 3():S149-53. PubMed ID: 15190298
    [No Abstract]   [Full Text] [Related]  

  • 2. The value of positron emission tomography (PET) imaging in disease staging and therapy assessment.
    Jerusalem G; Hustinx R; Beguin Y; Fillet G
    Ann Oncol; 2002; 13 Suppl 4():227-34. PubMed ID: 12401695
    [No Abstract]   [Full Text] [Related]  

  • 3. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Cremerius U; Fabry U; Wildberger JE; Zimny M; Reinartz P; Nowak B; Schaefer W; Buell U; Osieka R
    Bone Marrow Transplant; 2002 Jul; 30(2):103-11. PubMed ID: 12132049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
    Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
    Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
    Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial.
    Downey RJ; Akhurst T; Ilson D; Ginsberg R; Bains MS; Gonen M; Koong H; Gollub M; Minsky BD; Zakowski M; Turnbull A; Larson SM; Rusch V
    J Clin Oncol; 2003 Feb; 21(3):428-32. PubMed ID: 12560430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
    Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
    Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation.
    Escobar IG; Alonso PT; Barrigon DC; Perez-Simon JA; Mateos Manteca MV; San Miguel Izquierdo JF
    Ann Nucl Med; 2008 May; 22(4):251-60. PubMed ID: 18535875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography imaging in evaluation of cancer patients.
    Kumar R; Bhargava P; Bozkurt MF; Zhuang H; Potenta S; Alavi A
    Indian J Cancer; 2003; 40(3):87-100. PubMed ID: 14716112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncological applications of FDG PET imaging.
    Delbeke D
    J Nucl Med; 1999 Oct; 40(10):1706-15. PubMed ID: 10520713
    [No Abstract]   [Full Text] [Related]  

  • 12. [The impact of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) on planning of radiotherapy].
    Dizendorf E; Baumert B; von Schulthess GK; Luetolf UM; Steinert HC
    Ter Arkh; 2001; 73(10):11-4. PubMed ID: 11763507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of PET for evaluation of treatment response in oncology].
    Bourguet P
    Cancer Radiother; 2006 Nov; 10(6-7):334-7. PubMed ID: 16950641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Gentzler RD; Evens AM; Rademaker AW; Weitner BB; Mittal BB; Dillehay GL; Petrich AM; Altman JK; Frankfurt O; Variakojis D; Singhal S; Mehta J; Williams S; Kaminer L; Gordon LI; Winter JN
    Br J Haematol; 2014 Jun; 165(6):793-800. PubMed ID: 24628515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional imaging for assessment of therapy.
    Schwaiger M
    Br J Radiol; 2002 Nov; 75 Spec No():S67-73. PubMed ID: 12519738
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [18 F-fluorodeoxyglucose positron emission tomography for characterization and initial staging of pancreatic tumors].
    Valinas R; Barrier A; Montravers F; Houry S; Talbot JN; Huguier M
    Gastroenterol Clin Biol; 2002 Oct; 26(10):888-92. PubMed ID: 12434099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging?
    Hoegerle S; Juengling F; Otte A; Altehoefer C; Moser EA; Nitzsche EU
    Radiology; 1998 Oct; 209(1):253-8. PubMed ID: 9769840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy.
    Dizendorf EV; Baumert BG; von Schulthess GK; Lütolf UM; Steinert HC
    J Nucl Med; 2003 Jan; 44(1):24-9. PubMed ID: 12515872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.